Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) Short Interest Up 140.9% in March

Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) was the recipient of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 26,500 shares, an increase of 140.9% from the February 29th total of 11,000 shares. Based on an average daily trading volume, of 8,800 shares, the short-interest ratio is currently 3.0 days. Currently, 0.7% of the shares of the company are sold short.

Institutional Investors Weigh In On Cryo-Cell International

Several hedge funds have recently bought and sold shares of CCEL. Cerity Partners LLC purchased a new stake in Cryo-Cell International in the 4th quarter worth approximately $83,000. Northern Trust Corp purchased a new position in shares of Cryo-Cell International during the 4th quarter valued at approximately $151,000. Finally, Vanguard Group Inc. lifted its position in shares of Cryo-Cell International by 13.7% during the 3rd quarter. Vanguard Group Inc. now owns 83,883 shares of the company’s stock valued at $441,000 after buying an additional 10,095 shares in the last quarter. Hedge funds and other institutional investors own 10.44% of the company’s stock.

Cryo-Cell International Trading Down 6.8 %

NYSEAMERICAN CCEL traded down $0.54 during trading hours on Friday, reaching $7.46. The stock had a trading volume of 38,046 shares, compared to its average volume of 17,736. Cryo-Cell International has a 52-week low of $2.95 and a 52-week high of $8.15. The company’s fifty day moving average is $5.69. The stock has a market cap of $61.84 million, a PE ratio of -6.54 and a beta of 0.41.

Cryo-Cell International (NYSEAMERICAN:CCEL) last released its quarterly earnings data on Wednesday, February 28th. The company reported $0.26 EPS for the quarter. Cryo-Cell International had a negative return on equity of 120.29% and a negative net margin of 30.38%. The business had revenue of $7.88 million for the quarter.

About Cryo-Cell International

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.